Higashi, Yukihito
Miyata, Tetsuro
Shigematsu, Hiroshi
Origasa, Hideki
Fujita, Masatoshi
Matsuo, Hiroshi
Naritomi, Hiroaki
Matsuda, Hiroaki
Nakajima, Masahide
Awano, Hideto
Article History
Received: 25 April 2017
Accepted: 13 June 2017
First Online: 21 July 2017
Competing Interests
: Y.H. received consulting fees from Mitsubishi Tanabe Pharma Corporation related to this study, as well as honoraria and grants from Teijin Pharma Limited, Boehringer Ingelheim GmbH, Merck Sharp & Dohme Corporation, Sanofi Kabushiki Kaisya, AstraZeneca Kabushiki Kaisya, Kyowa Hakko Kirin Company Limited, Takeda Pharmaceutical Company Limited, Astellas Pharma Incorporated, Daiichi Sankyo Company Limited, Mochida Pharmaceutical Company Limited, Nihon Kohden Corporation, Shionogi Company Limited, Nippon Sigmax Company Limited, Sanwa Kagaku Kenkyusho Company Limited, Unex Corporation, and Kao Corporation, and honoraria from Radiometer Limited, Omron Corporation, Sumitomo Dainippon Pharma Company Limited, Otsuka Pharmaceutical Company Limited, Torii Pharmaceutical Company Limited, Kowa Company Limited, Fujiyakuhin Company Limited, Amgen Astellas BioPharma Kabushiki Kaisya, Nippon Shinyaku Company Limited, Itamar Medical Limited, Bayer Holding Limited, Eli Lilly Kabushiki Kaisya, and Ono Pharmaceutical Company Limited. T.M. received consulting fees from Mitsubishi Tanabe Pharma Corporation related to this study, as well as honoraria and grants from Sanofi Kabushiki Kaisya, Daiichi Sankyo Company Limited, and Mitsubishi Rayon Cleansui Company, Limited, and honoraria from Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim GmbH, Mochida Pharmaceutical Company Limited, Kowa Company Limited, Nippon Shinyaku Company Limited, Bayer Holding Limited, Pfizer Inc., Taisho Toyama Pharmaceutical Company Limited, Otsuka Pharmaceutical Company Limited, Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Company Limited, Zeria Pharmaceutical Company Limited, W.L. Gore & Associates, and Toray industories, Inc. H.S. received consulting fees from Mitsubishi Tanabe Pharma Corporation related to this study, as well as honoraria from Mitsubishi Tanabe Pharma Corporation, Sanofi Co., Otsuka Pharm Co., Cook Japan Co., Kaken Pharm Co., Taisho Toyama Pharm Co., Asteras Pharm Co., Nihon Shinyaku Co., Toray Co., Bayer Pharm Co., Daiitchi Sankyo Co., Mitsubishi Rayon Clinsui Co., Nihon Gore Co., Integural Co., Life Science Co., Anges MG Co., Terumo BSN Co., and Kowa Co., and event support from Sanofi Co., Cook Japan Co., Nihon Gore Co., Integural Co., and LimbFix Co. H.O. received consulting fees from Mitsubishi Tanabe Pharma Corporation related to this study, as well as consulting fees from Bayer Healthcare Co, Ltd, review fees from PMDA (Japanese FDA), and was a member of the data monitoring board for Daiichi-Sankyo Co, Ltd. Masatoshi Fujita received consulting fees from Mitsubishi Tanabe Pharma Corporation related to this study, but has no other disclosures to report. H. Matsuo received consulting fees from Mitsubishi Tanabe Pharma Corporation related to this study, as well as honoraria from Mitsubishi Tanabe Pharma Corporation, Aspen Japan Kabushiki Kaisya, Otsuka Pharmaceutical Company Limited, Kaken Pharmaceutical Company Limited, General Electric Company, Kowa Pharmaceutical Company Limited, Zeria Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Taisho Toyama Pharmaceutical Company Limited, Toshiba Medical Systems Corporation, Mitsubishi Tanabe Pharma Corporation, Nippon Sigmax Company Limited, Japanese Society of Sonographers, Novartis Pharma Kabushiki Kaisya, Bayer Holding Limited, Hitachi Aloka Medical Limited, Fukuda Denshi Company Limited, and Medicus Suppan Publishers Company Limited. H.N. received consulting fees from Mitsubishi Tanabe Pharma Corporation related to this study, as well as honoraria from Mitsubisshi Tanabe Pharma Corporation, Otsuka Pharmaceutical Company Limited, Pfizer Inc., Boeringer Ingelheim Japan Inc., AstraZeneca Kabushiki Kaisha, Nippon Sigmax Company Limited, Nakayama Shoten Co. Ltd, and Shindan Co. Ltd, and consulting fees from EPS Corporation. H. Matsuda is an employee of Mitsubishi Tanabe Pharma Corporation. M.N. is an employee of Mitsubishi Tanabe Pharma Corporation. H.A. is an employee of Mitsubishi Tanabe Pharma Corporation.